Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1425-1432

  Hotta, Tsukasa ^a   Takifuji, Katsunari ^a   Arii, Kazuo ^a   Yokoyama, Shozo ^a   Matsuda, Kenji ^a   Higashiguchi, Takashi ^a   Tominaga, Toshiji ^a   Oku, Yoshimasa ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; l LV 5FU

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; UNIVARIATE ANALYSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING;

EID: 33645808955     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Le Voyer TE, Sigurdson ER, Hanlon AL et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003.
2. Yamaue H, Tanimura H, Kono N et al: Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer. Anticancer Res 23: 2559-2564, 2003.
3. Francini G, Petrioli R, Lorenzini L et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterol 106: 899-906, 1994.
4. Piedbois P and Michiels S: Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-analysis based on 2,751 patients. Proc ASCO 22(abstr #1180): 294, 2003.
5. Evans RM, Laskin JD and Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981.
6. Petrelli N, Douglass HO, Herrera L et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
7. Petrelli N, Herrera L, Rustum Y et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559-1565, 1987.
8. Wolmark N, Rockette H, Fisher B et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
9. Zhang ZG and Rustum YM: Pharmacologic rationale for fluoropyrimidine- leucovorin combination: biochemical mechanisms. Semin Oncol 19: 46-50, 1992.
10. Scheithauer W, Kornek G, Marczell A et al: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 15: 908-914, 1997.
11. Goldberg RM, Hatfield AK, Kahn M et al: Prospectively randomized North Central Cancer Treatment Group Trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15: 3320-3329, 1997.
12. UICC: TNM Classification of Malignant Tumors. 4th Ed. Berlin Heidelberg, New York: Springer-Verlag, 1997.
13. Haydon A: Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J 33: 119-124, 2003.
14. Saltz L: Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology 14: 47-50, 2000.
15. Poon MA, O'Connell MJ, Wieand HS et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
16. De Gramont A, Bosset JF, Milan C et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997.
17. Cutsem EV, Twelves C and Cassidy J et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
18. Hoff PM, Ansari R, Batist G et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
19. De Gramont A, Figer A, Seymour M et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
20. Cunningham D, Pyrhönen S, James RD et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
21. Rougier P, Cutsem EV, Bajetta E et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 552: 1407-1412, 1998.
22. Saltz LB, Cox JV, Blanke C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
23. Saltz LB, Niedzwiecki D, Hollis D et al: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc ASCO 23(abstr #3500): 261, 2004.
24. Goldberg RM, Sargent DJ, Morton RF et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
25. Bécouarn Y, Ychou M, Ducreux M et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16: 2739-2744, 1998.
26. Díaz-Rubio E, Sastre J, Zaniboni A et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9: 105-108, 1998.
27. Maindrault-Goebel F, Louvet C, André T et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 35: 1338-1342, 1999.
28. De Gramont A, Vignoud J, Tournigand C et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
29. André T, Bensmaine MA, Louvet C et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560-3568, 1999.
30. Maindrault-Goebel F, de Gramont A, Louvet C et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37: 1000-1005, 2001.
31. Cutsem EV, Hoff PM, Harper P et al: Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 90: 1190-1197, 2004.
32. Cassidy J, Tabernero J, Twelves C et al: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
33. Cunningham D, Humblet Y, Siena S et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
34. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.